CN110200960A - Genistein is preparing the purposes in the drug for preventing or treating African swine fever - Google Patents
Genistein is preparing the purposes in the drug for preventing or treating African swine fever Download PDFInfo
- Publication number
- CN110200960A CN110200960A CN201910524468.3A CN201910524468A CN110200960A CN 110200960 A CN110200960 A CN 110200960A CN 201910524468 A CN201910524468 A CN 201910524468A CN 110200960 A CN110200960 A CN 110200960A
- Authority
- CN
- China
- Prior art keywords
- genistein
- drug
- purposes
- swine fever
- african swine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Abstract
The present invention provides Genistein and is preparing the purposes in the drug for preventing and treating African swine fever.Wherein, for Genistein when preparing the purposes in the drug for preventing African swine fever, dosage is the 1-2g/ previous day.For Genistein when preparing the purposes in the drug for treating African swine fever, dosage is the 2-20g/ previous day, and 7 days dosages of a dosage period are that preceding 2 days dosages are the 2-4g/ previous day, and latter 5 days are the 4-20g/ previous day.The present invention also provides Genisteins and other compositions use in conjunction to prepare the purposes in the pharmaceutical preparation for preventing and treating African swine fever jointly.
Description
Technical field
The present invention relates to a kind of medicinal usage more particularly to Genistein in preparation for preventing or treating African swine fever
Drug in purposes, belong to pharmaceutical technology field.
Background technique
Genistein is dissolved in DMSO and ethyl alcohol, is practically insoluble in water, and structure is as follows:
Genistein is derived from the isoflavone compound of bean and dentation plant, chemistry entitled 4 ', 5,7-
Trihydroxy-isoflavone.Genistein have prevent early atherosclerosis and chronic vascular disease, antitumor, women's climacteric
The multiple pharmacological effects such as phase syndrome and bioactivity.Genistein is strength tyrosine protein kinase and topoisomerase
Inhibitor, by the regulation to oncogene, to realize that multipath inhibits the growth and transfer of tumour.In vitroandin vivotrial and
Epidemiology shows that Genistein has inhibiting effect to kinds of tumors, such as breast cancer, prostate cancer, kidney, gastric cancer, knot
The carcinoma of the rectum, bladder cancer, lung cancer, uterine cancer, cutaneum carcinoma, leukaemia, lymthoma, neuroblastoma and head and neck cancer etc..
Genistein is practically insoluble in water, poor water solubility, the system being prepared by traditional formulation method
Agent, it is difficult to reach the bioavilability for the treatment of diseases demands after oral administration, while also greatly limit the type that preparation is made, such as
The dosage forms such as soluble powder or intravenous administration formulation.In addition, the content of Genistein in the formulation is lower, and controlled to reach
Drug concentration is treated, curative effect can only be improved by increasing the dosage of preparation, but increase hair again to a certain extent in this way
The risk of raw adverse reaction, but also will increase drug cost.
African swine fever (African Swine fever, East African Swine fever, ASF), is a kind of urgency
Property, generate heat the very high filterable virus of infectiousness caused by swine disease, it is characterized in that pathogenic process is short, but the death rate is up to
100%, clinical manifestation is fever, skin cyanosis, lymph node, kidney, the obvious bleeding of gastrointestinal mucosa.
In recent years, though have part treatment African swine fever medicament research and development come out, its therapeutic effect is slow, the state of an illness easily repeatedly,
Treatment is not thorough, and African swine fever rapid onset, infectiousness are strong, and mortality in acute phase is high, and the animal of virus infection can treated mostly
It is dead in the process, though part infection pig remission, but the probability of disease relapse is larger, and some drugs contain a large amount of resist
Raw element, after medication, causes to leave a large amount of antibiotic in vivo.On the other hand, the Chinese materia medica preparation mouth currently used for treatment African swine fever
It is poor to take therapeutic effect, and most Antibacterial Constituents can be digested system fast decoupled and metabolism, lose therapeutic effect.Mesh
Before, there are no the oral drug for developing quick, thorough, efficient and safe treatment African swine fever, infect after African swine fever only
Slaughter at once, the anti-spread path of isolation can be taken.
Summary of the invention
The present invention provides efficient one kind, quick, cure rate height and safety to solve above-mentioned problems of the prior art
Treatment African swine fever method.
The present invention provides Genistein and is preparing the purposes in the drug for preventing and treating African swine fever.
Wherein, the Genistein is preparing the purposes in the drug for preventing African swine fever, dosage 1-
The 2g/ previous day.
Wherein, the Genistein is preparing the purposes in the drug for treating African swine fever, dosage 2-
The 20g/ previous day.
Above-mentioned Genistein is 7 days preparing the purposes in the drug for treating African swine fever, a dosage period,
It can be according to state of an illness interruption or continual administration multiple periods.
Wherein, the Genistein is preparing the purposes in the drug for treating African swine fever, a dosage period 7
It dosage is that preceding 2 days dosages are the 2-4g/ previous day, and latter 5 days are the 4-20g/ previous day.
Above-mentioned Genistein is preparing the purposes in the drug for preventing or treating African swine fever, and the drug is straight
Connect and take or taken as additive, form be tablet, capsule, suspension, solution, emulsion, injection, ointment,
Gelling agent, film, pill, granule or powder.
Further, Genistein is preparing the purposes in the drug for preventing or treating African swine fever, the medicine
Contain Genistein inclusion compound in object, which is made of Genistein and inclusion agents, the use of the two
Amount is in parts by weight are as follows: 1-100 parts of Genistein, 5-800 parts of inclusion agents；Wherein, the inclusion agents are selected from cyclodextrin or ring
Dextrin derivative is selected from alpha-cyclodextrin, gamma-cyclodextrin, hydroxyethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, dihydroxypropyl β-
Cyclodextrin, methyl-B-cyclodextrin, glucose ring dextrin, maltose cyclodextrin, maltotriose cyclodextrin, carboxymethyl cyclodextrin, sulphur
The combination of one or more of alkyl cyclodextrins；Inclusion agents are more preferably hydroxypropyl-β-cyclodextrin, dihydroxypropyl β-ring
The combination of dextrin or hydroxypropyl-β-cyclodextrin and glucose ring dextrin by weight 1:2.
Further, Genistein is preparing the purposes in the drug for preventing or treating African swine fever, the medicine
In object contain Genistein solid dispersions, the Genistein solid dispersions by Genistein and matrix preparation and
At the two weight ratio is 1:2-6, and the matrix is selected from Macrogol 6000, Macrogol 4000, polyethylene glycol 2000, gathers
In ethylene glycol 1500, cetomacrogol 1000, odium stearate, glycerin gelatine, poloxamer, stearic acid and glycerol monostearate acid
It is one or more of；It is preferred that Macrogol 4000.
The present invention also provides Genisteins and the Genistein and other compositions use in conjunction to prepare for preventing
With the purposes in the pharmaceutical preparation for the treatment of African swine fever, the other compositions are selected from lauric monoglyceride, gallic acid laurel
One or more of alcohol ester, apiolin, L- carragheen, L- Polaprezinc, resveratrol, phenylbutyrate sodium or Enrofloxacin.
Present invention firstly discovers that Genistein has good prevention or therapeutic effect for African swine fever, there is treatment
Effect is fast, control the state of an illness be not easy repeatedly, thorough treatment, it is highly-safe the advantages that, solve at present treatment African swine fever technology
The problems such as existing therapeutic effect is poor.
Specific embodiment
Following embodiments of the invention be only to clearly illustrate example of the present invention, and not be to the present invention
Embodiment restriction.For those of ordinary skill in the art, it can also make on the basis of the following description
Other various forms of variations or variation.There is no necessity and possibility to exhaust all the enbodiments.And these belong to this
The obvious changes or variations that the spirit of invention is extended out are still in the protection scope of this invention.
Embodiment 1: the preparation of Genistein dry suspensoid agent
Prescription information
Preparation method:
Genistein is added in 300ml ethyl alcohol, stirring and dissolving, it is rear that beta-cyclodextrin and magnetic agitation is added, then
It is concentrated, dry, pulverize, cross 120 meshes；Filler, disintegrating agent, suspending agent sieve with 100 mesh sieve respectively, spare.By the title of recipe quantity
Genistein inclusion compound, lactose and mannitol, carboxyrnethyl starch sodium, xanthan gum mixing are taken, stirring 30 minutes or more, mixing was equal
It is even.The saccharin sodium of recipe quantity, flavoring pineapple essence are set in remaining ethyl alcohol and dissolved, is adhesive, softwood processed.The granulation of 20 meshes, 55-60
DEG C drying；18 mesh sieves.Fill compound membrane bag or bottle.
Embodiment 2: the preparation of Genistein dry suspensoid agent
Prescription information
Preparation method:
Genistein is added in 720ml ethyl alcohol, stirring and dissolving, simultaneously magnetic force stirs rear addition hydroxypropyl-β-cyclodextrin
It mixes, is then concentrated, dry, pulverize, cross 120 meshes；Filler, disintegrating agent, suspending agent sieve with 100 mesh sieve respectively, spare.By prescription
Amount weighs Genistein inclusion compound, sucrose and mannitol, hydroxypropul starch, xanthan gum mixing, stirring 30 minutes or more, mixes
It closes uniform.The stirring of 10% polyvinylpyrrolidone ethanol solution is added in the above-mentioned main and supplementary materials mixed, softwood processed.20 meshes
Granulation, 55-60 DEG C of drying；18 mesh sieves.Fill compound membrane bag or bottle.
Embodiment 3: the preparation of genistein dripping pills
100g Macrogol 4000 is taken by prescription, sets heating melting in 80 DEG C of water-baths, the goldspink that 50g is added under stiring is different
Flavine, stirring makes it be uniformly dispersed under 80 DEG C of heat preservations, and medical fluid is transferred in pill dripping machine constant temperature preserving jar, drips fast 60 drops/minute,
Coolant is atoleine, under the conditions of coolant temperature is 15 DEG C, adjusts dripping pill ball weight 60mg, dripping pill is made, removes dripping pill table
Face coolant, packing to get.
Embodiment 4: the preparation of genistein dripping pills
150g Macrogol 6000 is taken by prescription, sets heating melting in 80 DEG C of water-baths, the goldspink that 50g is added under stiring is different
Flavine, stirring makes it be uniformly dispersed under 80 DEG C of heat preservations, and medical fluid is transferred in pill dripping machine constant temperature preserving jar, drips fast 60 drops/minute,
Coolant is atoleine, under the conditions of coolant temperature is 5 DEG C, adjusts dripping pill ball weight 50mg, dripping pill is made, removes dripping pill surface
Coolant, packing to get.
Embodiment 5: the preparation of Genistein capsule
Prescription information
Preparation method:
Genistein is added in 350ml ethyl alcohol, stirring and dissolving, simultaneously magnetic force stirs rear addition dihydroxypropyl beta-cyclodextrin
It mixes, is then concentrated, dry, pulverize, cross 120 meshes；Filler, disintegrating agent, suspending agent sieve with 100 mesh sieve respectively, spare.By prescription
Amount weighs Genistein inclusion compound, lactose and mannitol, carboxyrnethyl starch sodium, tragacanth mixing, stir 30 minutes or more,
It is uniformly mixed.The saccharin sodium of recipe quantity, flavoring pineapple essence are set in remaining 60% ethyl alcohol and dissolved, is adhesive, softwood processed.20 meshes
Granulation, 55-60 DEG C of drying；18 mesh sieves.Fill No. 0 capsule.
Embodiment 6: the preparation of Genistein capsule
Prescription information
Preparation method:
Genistein is added in 700ml ethyl alcohol, stirring and dissolving, it is rear that glucose ring dextrin and magnetic agitation is added,
Then it is concentrated, dry, pulverize, cross 120 meshes；Filler, disintegrating agent, suspending agent sieve with 100 mesh sieve respectively, spare.By recipe quantity
Weigh Genistein inclusion compound, lactose, it is low replace light propyl cellulose, xanthan gum mixing, stirring 30 minutes or more, mixing
Uniformly.The saccharin sodium of recipe quantity, flavoring pineapple essence are set in remaining 60% ethyl alcohol and dissolved, is adhesive, softwood processed.20 mesh Shai Zhi
Grain, 55-60 DEG C of drying；18 mesh sieves.Fill No. 0 capsule.
7 pharmacodynamic test 1 of embodiment
28 6 ± 1 monthly ages of pig farm, 80 ± 5kg of weight, the boar for infecting disease stage African swine fever early period, this stage
Symptom predominantly generate heat (up to 40~42 DEG C), be slow in action, appetite is low, expiratory dyspnea, part cough, eye, nose have serosity or
Mucopus sexual secretion.
28 pigs are divided into 4 groups, every group 7, oral medication are carried out to every group of pig, administration mode is as follows:
1st group: the dry suspensoid agent of 2 days daily 1g containing Genistein of embodiment 1 before every pig, latter 5 days daily
The dry suspensoid agent of the 3g containing Genistein of embodiment 1 is taken, it is accumulative continuously to take 7,
2nd group: the dry suspensoid agent of 2 days daily 2g containing Genistein of embodiment 2 before every pig, latter 5 days daily
The dry suspensoid agent of the 3g containing Genistein of embodiment 2 is taken, it is accumulative continuously to take 7,
3rd group: the capsule of 2 days daily 1g containing Genistein of embodiment 3 before every pig, latter 5 days daily
The capsule of the 4g containing Genistein of embodiment 3, it is accumulative continuously to take 7,
4th group: the capsule of 2 days daily 1.5g containing Genistein of embodiment 4 before every pig often takes daily for latter 5 days
It is accumulative continuously to take 7 with the capsule of the 8g containing Genistein of embodiment 4.
Shown in 4 groups of therapeutic effect table 1.
Table 1
Note: the normal body temperature of Adult Pig is 38 DEG C~39.5 DEG C
8 pharmacodynamic test 2 of embodiment
28 pigs after the treatment of embodiment 7 have no that any pig has recurrence after observing January.
The pharmacodynamic test of 9 drug combination of embodiment
28 6 ± 1 monthly ages of pig farm, 80 ± 5kg of weight, the boar for infecting disease stage African swine fever early period are taken, is divided into 4
Group, carries out oral medication to every group of pig, administration mode is on the basis of the administration of embodiment 7, and every adds 300mg by every group 7
Enrofloxacin, after even served 7 days, all pigs show that feed improves and body temperature is normal.And compared with the data of table 1, more
Pig realizes feed improvement for 3 days before the treatment and body temperature is normal.After observing January, have no that any pig has recurrence.
Claims (10)
1. Genistein is preparing the purposes in the drug for preventing or treating African swine fever.
2. Genistein as described in claim 1 is preparing the purposes in the drug for preventing African swine fever, feature
It is, dosage is the 1-2g/ previous day.
3. Genistein as described in claim 1 is preparing the purposes in the drug for treating African swine fever, feature
It is, dosage is the 2-20g/ previous day.
4. Genistein as claimed in claim 3 is preparing the purposes in the drug for treating African swine fever, feature
It is, a dosage period is 7 days.
5. Genistein as claimed in claim 4 is preparing the purposes in the drug for treating African swine fever, feature
It is, 7 days dosages of a dosage period are that preceding 2 days dosages are the 2-4g/ previous day, and latter 5 days are 4-20g/ head
It.
6. Genistein as described in claim 1 is preparing the purposes in the drug for preventing or treating African swine fever,
It is characterized in that, the drug is directly to take or take as additive, form is tablet, capsule, suspension, solution
Agent, emulsion, injection, ointment, gelling agent, film, pill, granule or powder.
7. Genistein as claimed in claim 6 is preparing the purposes in the drug for preventing or treating African swine fever,
It is characterized in that, containing Genistein inclusion compound in the drug, the Genistein inclusion compound is by Genistein and packet
Mixture composition, the dosage of the two is in parts by weight are as follows: 1-100 parts of Genistein, 5-800 parts of inclusion agents.
8. Genistein as claimed in claim 7 is preparing the purposes in the drug for preventing or treating African swine fever,
It is characterized in that, the inclusion agents are selected from cyclodextrin or cyclodextrine derivatives, it is selected from alpha-cyclodextrin, gamma-cyclodextrin, ethoxy-
Beta-cyclodextrin, hydroxypropyl-β-cyclodextrin, dihydroxypropyl beta-cyclodextrin, methyl-B-cyclodextrin, glucose ring dextrin, malt saccharide ring
The combination of one or more of dextrin, maltotriose cyclodextrin, carboxymethyl cyclodextrin, sulfoalkyl cyclodextrin.
9. Genistein as claimed in claim 6 is preparing the purposes in the drug for preventing or treating African swine fever,
It is characterized in that, containing Genistein solid dispersions in the drug, the Genistein solid dispersions are different by goldspink
Flavine and matrix are prepared, the two weight ratio be 1:2-6, the matrix be selected from Macrogol 6000, Macrogol 4000,
Polyethylene glycol 2000, polyethylene glycol 1500, cetomacrogol 1000, odium stearate, glycerin gelatine, poloxamer, stearic acid and list
One or more of glycerol stearate acid.
10. Genistein as described in claim 1 is preparing the purposes in the drug for preventing or treating African swine fever,
It is characterized in that, the Genistein and other compositions use in conjunction；The other compositions are selected from lauric monoglyceride, do not have
One in gallate-based laurel alcohol ester, apiolin, L- carragheen, L- Polaprezinc, resveratrol, phenylbutyrate sodium or Enrofloxacin
Kind is several.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910524468.3A CN110200960A (en) | 2019-06-18 | 2019-06-18 | Genistein is preparing the purposes in the drug for preventing or treating African swine fever |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910524468.3A CN110200960A (en) | 2019-06-18 | 2019-06-18 | Genistein is preparing the purposes in the drug for preventing or treating African swine fever |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110200960A true CN110200960A (en) | 2019-09-06 |
Family
ID=67793218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910524468.3A Pending CN110200960A (en) | 2019-06-18 | 2019-06-18 | Genistein is preparing the purposes in the drug for preventing or treating African swine fever |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110200960A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112089726A (en) * | 2020-08-18 | 2020-12-18 | 河南佰景生物科技有限公司 | Application of special amino acid derivative in preparation of preparation for preventing and controlling African swine fever |
| US20220273573A1 (en) * | 2020-10-16 | 2022-09-01 | Humanetics Corporation | Solid dispersion genistein compositions and methods of making and using the same |
-
2019
- 2019-06-18 CN CN201910524468.3A patent/CN110200960A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| JOÃO COELHO等: "Functional characterization and inhibition of the type II DNA topoisomerase coded by African swine fever virus", 《VIROLOGY》 * |
| 新乡大北农: "你必须知道丨这些疫苗和药物或能有效控制非洲猪瘟！", 《HTTPS://WWW.SOHU.COM/A/291070614_769261》 * |
| 杨有福: "防治非洲猪瘟疫苗和药物还有多远？", 《微信公众号：PSY应用研究院》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112089726A (en) * | 2020-08-18 | 2020-12-18 | 河南佰景生物科技有限公司 | Application of special amino acid derivative in preparation of preparation for preventing and controlling African swine fever |
| US20220273573A1 (en) * | 2020-10-16 | 2022-09-01 | Humanetics Corporation | Solid dispersion genistein compositions and methods of making and using the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107405309B (en) | Tune for the orlistat and acarbose for the treatment of obesity and related metabolic disturbance releases composition | |
| CN101623258B (en) | Ranitidine hydrochloride lipidosome capsule and new application thereof | |
| CN101829061A (en) | Taxol nanoparticle composition and preparation method thereof | |
| CN110200960A (en) | Genistein is preparing the purposes in the drug for preventing or treating African swine fever | |
| CN107714642A (en) | A kind of oral solution of EV71 viruses and CVA16 viral inhibitors and preparation method thereof | |
| CN103191141B (en) | Application of 3-methoxyl mangiferin in preparing medicine used for treating post-stroke depression | |
| CN102949377B (en) | Acetazolamide sustained-release capsule and preparation method thereof | |
| CN105142644A (en) | Onapristone polymorphic forms and methods of use | |
| CN106038584A (en) | Colloidal bismuth pectin capsule preparation and preparation method thereof | |
| CN105055363A (en) | Acotiamide hydrochloride sustained-release drug and preparation method thereof | |
| CN102125540A (en) | Pharmaceutically acceptable composition containing ambroxol in non-salt form | |
| KR20090086686A (en) | Pharmaceutical composition comprising silymarin with improved dissolution rate and method for preparing the same | |
| WO2016050193A1 (en) | Oral formulation of a-nor-5α androstane compound | |
| CN101120937A (en) | Application of chlorogenic acid in preparing medicine with cervical cancer preventing and treating efficiency | |
| CN1312157C (en) | Halogenated dihydroartemisine, preparation and use thereof | |
| CN111686084B (en) | Application of berberine hydrochloride oryzanol tablets in treating diabetes | |
| CN108653243A (en) | A kind of preparation method of sustained release Tilmicosin microcapsule powder | |
| CN106474097B (en) | Anticancer agent | |
| CN101491493A (en) | Ferulic acid piperazine slow-release medicine preparation | |
| CN104721827A (en) | Insoluble antifungal medicament solid dispersion and preparation method thereof | |
| WO2019201268A1 (en) | Drug used for preventing and/or treating pain and/or fever, combination product, and use thereof | |
| CN107375225B (en) | Level release formulation of a kind of succinic acid furan Luo Qu and preparation method thereof | |
| CN103432082A (en) | Glucosamine composition and preparation method thereof | |
| TWI835118B (en) | Brexpiprazole oral film inclusion complex, preparation method and use thereof | |
| CN116421634B (en) | Cs-4 cordyceps sinensis powder extract and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190906 |